Tirzepatide

Overview

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and Company. Often referred to as a “twincretin” due to its engagement of both major incretin receptor systems, tirzepatide represents a paradigm shift in the pharmacological treatment of type 2 diabetes and obesity by harnessing the complementary and synergistic actions of GIP and GLP-1 receptor signaling.

The molecule was approved by the FDA in May 2022 under the brand name Mounjaro for the treatment of type 2 diabetes mellitus, and in November 2023 under the brand name Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Its clinical development code was LY3298176.

Tirzepatide is based on the native GIP(1-42) sequence rather than GLP-1, a deliberate design choice by Eli Lilly’s research team led by Dr. Tamer Coskun. The GIP backbone was selected because it provided a more favorable structural scaffold for achieving potent dual agonism. The peptide contains several engineered modifications including non-natural amino acids, a C-20 fatty diacid albumin-binding moiety, and sequence substitutions that confer GLP-1 receptor cross-reactivity while maintaining strong GIP receptor agonism.

Mechanism of Action

Tirzepatide simultaneously activates two incretin receptors with distinct but complementary downstream effects. This dual mechanism produces metabolic benefits that exceed those achievable through GLP-1 receptor agonism alone.

GIP Receptor Agonism

Tirzepatide binds with high affinity to the GIP receptor (GIPR), a class B GPCR expressed on pancreatic beta cells, adipocytes, osteoblasts, and neurons. On beta cells, GIPR activation stimulates cAMP production and potentiates glucose-dependent insulin secretion through PKA and Epac2 pathways, complementing GLP-1R-mediated insulinotropic effects. In adipose tissue, GIP receptor signaling promotes lipid uptake and storage in subcutaneous adipose depots, improving lipid buffering capacity and reducing ectopic fat deposition in liver and visceral compartments. This adipose tissue remodeling effect is thought to improve insulin sensitivity independently of weight loss.

GLP-1 Receptor Agonism

Despite being constructed on a GIP backbone, tirzepatide activates GLP-1R with approximately 5-fold lower potency than native GLP-1, which is nonetheless pharmacologically significant at therapeutic concentrations. GLP-1R activation contributes appetite suppression through hypothalamic and hindbrain circuits, suppresses glucagon secretion, and slows gastric emptying. The combination of GIPR and GLP-1R activation in the central nervous system produces enhanced satiety signaling through convergent neural pathways in the arcuate nucleus and area postrema.

Synergistic Metabolic Effects

Preclinical research by Samms et al. (2021) demonstrated that combined GIP and GLP-1 receptor activation produces synergistic weight loss in diet-induced obese mice that exceeds the additive effects of either receptor system alone. The proposed mechanism involves GIP-mediated enhancement of GLP-1 receptor sensitivity in hypothalamic neurons, amplifying the anorexigenic signal. Additionally, GIP receptor activation in brown and beige adipocytes enhances thermogenic capacity through upregulation of uncoupling protein 1 (UCP-1), contributing to increased energy expenditure.

Research Summary

Tirzepatide has been evaluated in an extensive clinical trial program demonstrating unprecedented efficacy in both glycemic control and weight reduction.

SURPASS Program (Type 2 Diabetes)

The SURPASS Phase III program comprised five pivotal trials evaluating tirzepatide in type 2 diabetes. Frias et al. (2021), published in the New England Journal of Medicine, reported results from SURPASS-2 comparing tirzepatide (5, 10, and 15 mg) to semaglutide 1 mg in 1,879 patients. Tirzepatide at all doses demonstrated superior HbA1c reduction versus semaglutide, with the 15 mg dose achieving a mean HbA1c reduction of 2.46% compared to 1.86% for semaglutide (p<0.001). Weight loss was also significantly greater with tirzepatide 15 mg (-12.4 kg versus -6.2 kg with semaglutide).

SURMOUNT Program (Obesity)

Jastreboff et al. (2022), published in the New England Journal of Medicine, reported SURMOUNT-1 results in 2,539 adults with obesity. At 72 weeks, tirzepatide 15 mg produced a mean weight reduction of 22.5% from baseline compared to 2.4% with placebo. An extraordinary 63% of participants in the 15 mg group achieved at least 20% weight loss, and 36% achieved at least 25% weight loss, outcomes that approach the weight reduction typically achieved with bariatric surgery procedures.

Obstructive Sleep Apnea

Malhotra et al. (2024), published in the New England Journal of Medicine, reported results from the SURMOUNT-OSA trial demonstrating that tirzepatide significantly reduced the apnea-hypopnea index (AHI) in patients with moderate-to-severe obstructive sleep apnea. The 15 mg dose reduced AHI by approximately 50-60% at 52 weeks, with many patients achieving clinically meaningful reductions below the diagnostic threshold, suggesting potential for disease remission in conjunction with weight loss.

Heart Failure with Preserved Ejection Fraction

Kosiborod et al. (2024), published in the New England Journal of Medicine, reported the SUMMIT trial results showing tirzepatide significantly reduced the composite of cardiovascular death or worsening heart failure events by 38% in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, establishing cardiovascular benefit beyond weight management.

Dosing in Published Research

Tirzepatide is an FDA-approved prescription medicine, sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management; both contain the same active drug and use the same titration ladder. The FDA-approved labeling specifies a stepwise schedule:

1. 2.5 mg injected subcutaneously once weekly for 4 weeks (a treatment-initiation dose, not a maintenance dose).
2. Increase to 5 mg once weekly.
3. If further control is needed, increase in 2.5 mg increments after at least 4 weeks at the current dose.
4. The labeled maximum is 15 mg once weekly; the full ladder is 2.5, 5, 7.5, 10, 12.5 and 15 mg.

These figures are drawn from FDA-approved prescribing information.

Safety and Side Effects

Tirzepatide carries an FDA boxed warning, the agency’s most serious warning category, for thyroid C-cell tumors. In rodent studies, tirzepatide caused thyroid C-cell tumors; it is not known whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Other labeled risks include

• Acute pancreatitis.
• Gallbladder disease, including gallstones and cholecystitis.
• Acute kidney injury secondary to dehydration.
• Diabetic retinopathy complications in patients with type 2 diabetes.
• Hypoglycemia when combined with insulin or insulin secretagogues.
• Severe gastrointestinal disease.
• Hypersensitivity reactions.

Because tirzepatide delays gastric emptying, it can reduce the effectiveness of oral hormonal contraceptives around the time of initiation and dose escalation. The most common adverse effects are gastrointestinal, including nausea, diarrhea, vomiting, constipation, and abdominal pain, generally dose-related and most pronounced during titration.

As with other agents that produce large reductions in body weight, a portion of the weight lost on tirzepatide is lean (muscle) mass. The drug should be used with caution around pregnancy. Tirzepatide is a prescription medication and should be used only under medical supervision; material sold outside the regulated pharmacy supply chain may differ in identity, dose, and purity from the approved product.

Current Research Status

Tirzepatide is an FDA-approved prescription medication, a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). It is supported by the SURPASS and SURMOUNT randomized controlled trial programs and by ongoing cardiovascular and heart-failure outcome studies. As with semaglutide, its approval reflects a regulatory benefit-risk judgment for defined populations under medical supervision, and the boxed warning and contraindications above apply.

Further reading: Tirzepatide Microdosing: What the Evidence Shows examines what the research does and does not support regarding lower-dose tirzepatide protocols.

Frequently Asked Questions